Bioservo Q1’23: Good start to 2023 on several fronts - Redeye

Redeye saw sales roughly in line with our expectations in the Q1 report, as deliveries of Carbonhand were made in the quarter. The costs was starting to trend lower as per the cost-cutting program. The fact that Carbonhand is now registered as a 510(k) by FDA opens up for sales in the US earlier than expected.

Länk till analysen i sin helhet: https://www.redeye.se/research/896754/bioservo-q123-good-start-to-2023-on-several-fronts?utm_source=finwire&utm_medium=RSS